Who owns Eton Pharmaceuticals Inc?
- Ticker: ETON
- CUSIP Number: 29772l108
Tip: Access positions for across all investors
Analyze quarterly positions in Eton Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Eton Pharmaceuticals stock
Who bought or sold Eton Pharmaceuticals Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Opaleye Management | 2.9M | $38M | 3% | Dec 2024 |
|
| EcoR1 Capital | 2.0M | $26M | 149% | Dec 2024 |
|
| Nantahala Capital Management | 1.1M | $15M | 12% | Dec 2024 |
|
| Vanguard Group | 1.1M | $14M | 4% | Dec 2024 |
|
| Westside Investment Management | 575k | $7.7M | -7% | Dec 2024 |
|
| Cannell Capital | 381k | $5.1M | 100% | Dec 2024 |
|
| BlackRock | 318k | $4.2M | 12% | Dec 2024 |
|
| Susquehanna International | 282k | $3.8M | 110% | Dec 2024 |
|
| Parkman Healthcare Partners | 277k | $3.7M | 6% | Dec 2024 |
|
| Geode Capital Management | 269k | $3.6M | -1% | Dec 2024 |
|
| Acadian Asset Management | 249k | $3.3M | 135% | Dec 2024 |
|
| Aristides Capital | 242k | $3.2M | 21% | Dec 2024 |
|
| Bridgeway Capital Management | 239k | $3.2M | -6% | Dec 2024 |
|
| Daniel D. Thurber | 231k | $3.1M | -3% | Dec 2024 |
|
| Connor, Clark & Lunn Investment Management | 215k | $2.9M | 231% | Dec 2024 |
|
| Paradigm Capital Management | 200k | $2.7M | -33% | Dec 2024 |
|
| Renaissance Technologies | 193k | $2.6M | 132% | Dec 2024 |
|
| Acuitas Investments | 186k | $2.5M | -68% | Dec 2024 |
|
| Millennium Management | 139k | $1.8M | 100% | Dec 2024 |
|
| UBS Group | 135k | $1.8M | 612% | Dec 2024 |
|
| Goldman Sachs Group | 130k | $1.7M | 100% | Dec 2024 |
|
| Thompson, Siegel, & Walmsley | 128k | $1.7M | 11% | Dec 2024 |
|
| Two Sigma Investments | 113k | $1.5M | 100% | Dec 2024 |
|
| State Street Corporation | 105k | $1.4M | 29% | Dec 2024 |
|
| Eudaimonia Asset Management | 95k | $1.3M | -26% | Dec 2024 |
|
| Qube Research & Technologies | 94k | $1.3M | 191% | Dec 2024 |
|
| Schonfeld Strategic Advisors | 90k | $1.2M | 421% | Dec 2024 |
|
| Northern Trust | 87k | $1.2M | 36% | Dec 2024 |
|
| Bank of New York Mellon | 74k | $989k | 0% | Dec 2024 |
|
| 683 Capital Management | 69k | $919k | 100% | Dec 2024 |
|
| Jane Street | 64k | $857k | 329% | Dec 2024 |
|
| Anchor Capital Advisors | 60k | $805k | 100% | Dec 2024 |
|
| Barclays | 55k | $731k | 100% | Dec 2024 |
|
| Jpmorgan Chase & Co | 52k | $692k | 7087% | Dec 2024 |
|
| Two Sigma Advisers | 50k | $662k | 100% | Dec 2024 |
|
| Citadel Advisors | 47k | $627k | 155% | Dec 2024 |
|
| Cubist Systematic Strategies | 43k | $576k | 423% | Dec 2024 |
|
| OMERS Administration Corporation | 38k | $505k | 100% | Dec 2024 |
|
| Simplex Trading | 36k | $484k | 100% | Dec 2024 |
|
| Marshall Wace | 36k | $482k | 75% | Dec 2024 |
|
| William Blair $ Company | 35k | $465k | 1% | Dec 2024 |
|
| Baader Bank | 28k | $373k | 100% | Dec 2024 |
|
| Jump Financial | 25k | $329k | 100% | Dec 2024 |
|
| Essex Investment Management | 24k | $326k | -10% | Dec 2024 |
|
| Springbok Capital Management | 24k | $323k | 100% | Dec 2024 |
|
| Citigroup | 22k | $293k | -17% | Dec 2024 |
|
| Envestnet Asset Management | 18k | $236k | 100% | Dec 2024 |
|
| Hillsdale Investment Management | 17k | $227k | 100% | Dec 2024 |
|
| CHICAGO TRUST Co NA | 17k | $222k | 0% | Dec 2024 |
|
| XTX Topco | 15k | $195k | 30% | Dec 2024 |
|
| Charles Schwab Investment Management | 13k | $176k | 0% | Dec 2024 |
|
| Morgan Stanley | 13k | $176k | 2695% | Dec 2024 |
|
| Engineers Gate Manager | 13k | $168k | 100% | Dec 2024 |
|
| Occudo Quantitative Strategies | 12k | $73k | 100% | Sep 2024 |
|
| Atom Investors | 12k | $161k | 100% | Dec 2024 |
|
| Balyasny Asset Management | 12k | $158k | 100% | Dec 2024 |
|
| Quantum Private Wealth | 12k | $153k | 0% | Dec 2024 |
|
| Bank of America Corporation | 11k | $148k | 5422% | Dec 2024 |
|
| Raymond James Financial | 11k | $147k | 100% | Dec 2024 |
|
| Point72 Asia | 11k | $141k | 18% | Dec 2024 |
|
| Raymond James & Associates | 10k | $62k | 0% | Sep 2024 |
|
| Leucadia National Corporation | 10k | $133k | 100% | Dec 2024 |
|
| Tower Research Capital | 6.4k | $86k | 100% | Dec 2024 |
|
| Point72 | 1.4k | $19k | 100% | Dec 2024 |
|
| Federated Investors | 1.4k | $19k | 100% | Dec 2024 |
|
| Truvestments Capital | 1.2k | $16k | 0% | Dec 2024 |
|
| Lazard Asset Management | 1.0k | $13k | 100% | Dec 2024 |
|
| Wells Fargo & Company | 1.0k | $13k | 100% | Dec 2024 |
|
| Royal Bank of Canada | 752.00 | $10k | 173% | Dec 2024 |
|
| Bnp Paribas Arbitrage, Snc | 350.00 | $4.7k | 0% | Dec 2024 |
|
| Advisor Group Holdings | 260.00 | $3.5k | -13% | Dec 2024 |
|
| SBI Securities | 141.00 | $1.9k | 100% | Dec 2024 |
|
Who sold out of Eton Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| ADAR1 Capital Management | Jun 2024 | 1.2k | $3.9k |
| Plante Moran Financial Advisors | Sep 2024 | 1.0k | $6.0k |
| Group One Trading | Sep 2024 | 722.00 | $4.3k |